EGFR and non-small cell lung carcinoma: Additionally, the results indicated that icotinib (HR 0.36, 95% CI 0.24–0.55), osimertinib (HR 0.17, 95% CI 0.11–0.26), and erlotinib (HR 0.42, 95% CI 0.19–0.94) could significantly prolong DFS compared to placebo or adjuvant chemotherapy in the NSCLC patients with EGFR mutations.